Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (114)
ARTG (90)
Australian public assessment report (AusPar) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (5)
2015 (8)
2014 (7)
2013 (13)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1993 (3)
1991 (2)

Search

Sponsor content

216 result(s) found, displaying 121 to 130

TARGIN oxycodone hydrochloride / naloxone hydrochloride anhydrous 80/40 mg modified release tablets blister pack (243272)

20 July 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TARGIN oxycodone hydrochloride / naloxone hydrochloride anhydrous 80/40 mg modified release tablets blister pack.
TARGIN oxycodone hydrochloride / naloxone hydrochloride anhydrous 60/30 mg modified release tablets blister pack (243252)

20 July 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TARGIN oxycodone hydrochloride / naloxone hydrochloride anhydrous 60/30 mg modified release tablets blister pack.
TENOPT 0.25% timolol 2.5mg/mL as maleate eye drops puffer pack Cancelled under Section 30(1) (c) of the Act

22 May 2019

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
TENOPT 0.5% timolol 5mg/mL as maleate eye drops puffer pack Cancelled under Section 30(1) (c) of the Act

22 May 2019

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MS CONTIN morphine sulfate pentahydrate 10mg controlled-release tablet blister pack Cancelled under Section 30(1)(c) of the Act

9 May 2019

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
SEVREDOL morphine sulfate pentahydrate 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

9 May 2019

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
AusPAR: Leuprorelin

24 October 2018

Australian public assessment report (AusPar)

Australian Public Assessment Report for Leuprorelin
DEPOCYT cytarabine 50mg/5mL injection vial Section 30(1)(c) of the Act

6 July 2018

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
Mundipharma Pty Ltd - Dressing, hydrophilic gel-forming Cancelled under Section 41GL(d) of the Act

27 June 2018

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
Mundipharma Pty Ltd - Bandage Cancelled under Section 41GL(d) of the Act

27 June 2018

Cancellation by sponsor

Requested by Mundipharma Pty Ltd

Pages

First page
Previous page
…
Page 9
Page 10
Page 11
Page 12
Current page 13
Page 14
Page 15
Page 16
Page 17
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.